X

    Xencor Inc (XNCR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.27
    +1.20 (+4.62%)

    Market Cap: $1.94B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +92.55%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.32
    Range$-1.04 - $0.22
    11 analysts
    EPS Revisions
    5
    0
    7d
    5
    0
    30d
    EPS Estimate Drift
    90d ago$-0.82-154.2%
    60d ago$-0.82-154.2%
    30d ago$-0.83-158.2%
    7d ago$-0.83-158.2%
    Current$-0.32
    Revenue Consensus
    $60M
    Range$10M - $115M
    13 analysts
    Dec 31, 2026
    EPS Consensus$-1.20
    Range$-2.23 - $0.04
    12 analysts
    Revenue Consensus
    $38M
    Range$-35046150 - $94M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.20---
    Sep 26EST
    		-$-0.32---
    Jun 26
    		$-0.29N/A+64.63%Beat+29.3%
    Mar 26
    		$-1.71$-0.75-128.00%Miss-159.1%
    Dec 25
    		$-0.09N/A+85.09%Beat+85.5%
    Sep 25
    		$-0.08N/A+88.89%Beat+88.7%
    Jun 25
    		$-0.41$-0.71+42.25%Beat+61.7%
    Mar 25
    		$-0.66$-0.58-13.79%Miss+40.5%
    Dec 24
    		$-0.62$-0.79+21.14%Beat-100.0%
    Sep 24
    		$-0.71$-1.02+30.39%Beat-77.5%
    Jun 24
    		$-1.07$-0.79-35.44%Miss-189.2%
    Mar 24
    		$-1.11$-0.77-44.16%Miss-8.8%
    Dec 23
    		$-0.31$-0.09-244.44%Miss-55.0%
    Sep 23
    		$-0.40$-0.71+43.66%Beat+27.3%
    Jun 23
    		$-0.37N/A+54.32%Beat+35.1%
    Mar 23
    		$-1.02$-0.66-54.55%Miss-361.5%
    Dec 22
    		$-0.20N/A+75.31%Beat-116.5%
    Sep 22
    		$-0.55$-0.72+23.61%Beat+20.3%
    Jun 22
    		$-0.57$-0.47-21.28%Miss-165.5%
    Mar 22
    		$0.39$-0.45+186.67%Beat+1075.0%
    Dec 21
    		$1.21$-0.10+1310.00%Beat+604.2%
    Sep 21
    		$-0.69$-0.70+1.43%Beat-213.6%
    Jun 21
    		$0.87$-0.55+258.18%Beat+242.6%
    Mar 21
    		$-0.04N/A+94.03%Beat+71.4%
    Dec 20
    		$-0.24$-0.46+47.83%Beat+48.9%
    Sep 20
    		$-0.22$-0.22+0.00%Beat-22.2%
    Jun 20
    		$-0.61$-0.50-22.00%Miss-117.9%
    Mar 20
    		$-0.14N/A+65.85%Beat-110.1%
    Dec 19
    		$-0.47$-0.41-14.63%Miss-46.9%
    Sep 19
    		$-0.18N/A+66.04%Beat-460.0%
    Jun 19
    		$-0.28$-0.45+37.78%Beat+39.1%
    Mar 19
    		$1.38$0.09+1433.33%Beat+322.6%
    Dec 18
    		$-0.32$-0.49+34.69%Beat-28.0%
    Sep 18
    		$0.05N/A+109.62%Beat+115.2%
    Jun 18
    		$-0.46$-0.57+19.30%Beat-206.7%
    Mar 18
    		$-0.62$-0.47-31.91%Miss-100.0%
    Dec 17
    		$-0.25$-0.35+28.57%Beat-19.0%
    Sep 17
    		$-0.33$-0.31-6.45%Miss-65.0%
    Jun 17
    		$-0.15$-0.23+34.78%Beat-
    Mar 17
    		$-0.31$-0.28-10.71%Miss-
    Dec 16
    		$-0.21$-0.32+34.38%Beat-
    Sep 16
    		$-0.20$-0.32+37.50%Beat-

    Key Metrics

    Valuation
    P/E Ratio-12.56EV/EBITDA-17.27x
    Price/FCF-9.93xFCF Yield-10.07%
    Profitability
    Profit Margin-155.60%Operating Margin-72.40%
    ROE-29.10%ROIC-25.78%
    Financial Health
    Debt/Equity0.21xInterest Coverage-5.79x
    Current Ratio6.39xQuick Ratio6.39x
    Trading Statistics
    Beta0.84Avg Volume1.32M
    52-Week High$30.6152-Week Low$7.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$27.67
    SMA 20$24.68
    SMA 50$20.05
    SMA 200$14.90
    EMA 10$26.94
    EMA 20$25.13
    EMA 50$21.14
    EMA 200$15.64

    MACD

    Line: 2.46Signal: 2.49Hist: -0.03

    ADX

    ADX: 65.8+DI: 33.3-DI: 15.4

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down4.0
    PSAR$30.51

    Bollinger Bands

    Upper Band$31.37
    Lower Band$17.99
    %B Position5422%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    63.7

    Momentum Oscillators

    Stoch %K65.1
    Stoch %D73.3
    Williams %R-38.4
    ROC (10d)17.9%
    Momentum4.14
    CCI (20d)53.0
    MFI (14d)62.2

    Volatility Measures

    ATR (14d)$1.51(5.5%)
    StdDev (20d)3.35
    Hist Vol66.5%(High)

    Volume Flow

    VWAP$26.94
    OBV10.9M
    AD Line-3.3M
    CMF (20d)0.192

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.3x
    VWMA (20d)$25.34

    Pivot Points

    R3$31.25
    R2$30.11
    R1$28.09
    Pivot Point$26.95
    S1$24.92
    S2$23.78
    S3$21.75

    Advanced Oscillators

    TSI44.87
    Ultimate Osc53.3
    KST480.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$51.22M$4.52M$28.24M$21.00M$43.61M$32.73M$52.79M$17.80M$23.91M$16.00M$50.97M$59.16M
    Cost of Revenue$0$0$2.58M$0$0$0$51.06M$0$0$0$3.23M$0
    Gross Profit$51.22M$4.52M$28.24M$21.00M$43.61M$32.73M$52.79M$17.80M$23.91M$16.00M$50.97M$59.16M
    Operating Expenses$88.29M$82.38M$81.86M$68.52M$76.78M$75.92M$65.97M$72.99M$79.28M$70.66M$78.32M$77.43M
    R&D$71.91M$64.67M$64.82M$54.37M$61.66M$58.58M$51.06M$58.23M$61.53M$56.87M$63.05M$64.94M
    SG&A$16.38M$17.71M$17.04M$14.15M$15.12M$17.34M$14.91M$14.77M$17.75M$13.79M$15.27M$12.49M
    Operating Income$-37,068,000$-77,862,000$-53,628,000$-47,519,000$-33,172,000$-43,183,000$-13,178,000$-55,197,000$-55,370,000$-54,663,000$-27,351,000$-18,270,000
    Interest Income$4.80M$5.46M$6.20M$6.54M$7.25M$7.54M$8.16M$7.54M$7.68M$8.55M$7.64M$5.02M
    Interest Expense$7.35M$4.70M$7.35M$7.67M$8.24M$8.66M$8.66M$9.03M$9.28M$9.68M$6.16M$7,000
    Income Before Tax$-21,919,000$-128,636,000$-4,266,000$-6,027,000$-31,075,000$-48,265,000$-44,583,000$-47,442,000$-68,782,000$-74,116,000$-12,648,000$-24,269,000
    Income Tax Expense$-190,000$280,000$2.39M$0$-250,000$367,000$1.62M$0$0$0$0$0
    Net Income$-21,729,000$-128,916,000$-6,653,000$-6,027,000$-30,825,000$-48,632,000$-46,200,000$-47,442,000$-68,782,000$-74,116,000$-26,310,000$-24,269,000
    EBITDA$-16,934,000$-126,956,000$-875,000$-3,963,000$-26,790,000$-46,571,000$-40,503,000$-47,792,000$-68,988,000$-76,864,000$-16,326,000$-30,011,000
    EBIT$-19,367,000$-129,395,000$-3,112,000$-4,900,000$-30,080,000$-47,138,000$-44,088,000$-45,953,000$-67,181,000$-72,988,000$-14,130,000$-29,285,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XNCR

    News

    Primecap Management Co. CA Invests $163.92 Million in Xencor, Inc. $XNCR

    Primecap Management Co. CA has acquired a significant new stake of $163.92 million in biopharmaceutical company Xencor, Inc. (NASDAQ:XNCR), totaling 10.18 million shares and representing a 13.69% ownership. Other institutional investors like BlackRock and Vanguard also hold substantial positions, with Xencor recently reporting a narrower-than-expected quarterly loss and exceeding revenue estimates. Despite a consensus "Hold" rating from analysts, the stock has shown strong price performance, opening at $29.30, near its one-year high.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    ADAR1 Capital Management LLC Invests $3.74 Million in Xencor, Inc. $XNCR

    ADAR1 Capital Management LLC has invested $3.74 million in Xencor, Inc. (NASDAQ:XNCR) by acquiring 232,560 shares during the second quarter. Other hedge funds have also increased their positions in the biopharmaceutical company, which recently reported better-than-expected earnings with revenue up 17.4% year-over-year. Analysts currently have a consensus "Hold" rating on Xencor, with an average price target of $24.86.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    Xencor (NASDAQ:XNCR) Reaches New 52-Week High - Here's Why

    Xencor (NASDAQ:XNCR) shares recently hit a new 52-week high of $28.4590, driven by the company exceeding its quarterly revenue and earnings estimates. Analysts' sentiment is mixed, with a consensus "Hold" rating and an average price target of $24.86, despite some recent upgrades. The biopharmaceutical company specializes in engineered protein therapeutics for autoimmune diseases, cancer, and neurological disorders.

    MarketBeat•8/24/26•
    Somewhat-Bullish

    Is Xencor (XNCR) Undervalued After Its Recent Share Price Surge?

    Xencor (XNCR) has seen a significant surge in its share price recently, with a 32.03% return over the last 30 days and 262.90% over the past year. Despite this, the company is still considered 5.3% undervalued against a fair value of $28.50, driven by its robust XmAb platform and efficient clinical trial strategy. However, potential risks include increased competition in TL1A programs and possible delays or underwhelming data from key trials like XmAb942 or XmAb412.

    Simply Wall Street•8/21/26•
    Somewhat-Bullish

    103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC

    DCF Advisers LLC recently acquired 103,736 shares of Xencor, Inc. (NASDAQ:XNCR) during the second quarter, establishing a new position valued at approximately $1.67 million. Other institutional investors also adjusted their holdings in the biopharmaceutical company, which recently reported better-than-expected quarterly revenue of $51.22 million and an adjusted loss of $0.29 per share. Despite trading near its 12-month high, analysts maintain an overall "Hold" rating for Xencor with an average price target of $24.86.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About XNCR

    Does XNCR pay dividends?
    Xencor Inc (XNCR) does not currently pay a regular dividend.
    What is XNCR's market cap?
    Xencor Inc (XNCR) has a market capitalization of $1.94B with a current stock price of $27.27.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In